No cookies!

Cookies disabled. It’s not us, it’s your browser. Your Web browser must have cookies enabled for you to use all of the site’s functions.

TOLERABIILITY

Xiidra had a demonstrated
safety profile in clinical trials1

Adverse reactions were evaluated across 5 clinical trials1

In 5 clinical studies, 1287 patients received at least one dose of Xiidra. Most patients (84%) were exposed to Xiidra for up to 12 weeks.1

170 patients were exposed to Xiidra for approximately 12 months.1

The most common adverse reactions while using Xiidra reported in 5-25% of patients were instillation site irritation, dysgeusia, and reduced visual acuity.1*

Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus, and sinusitis.1

*The same patient could have reported more than one event.

Want to learn more about Xiidra and Shire?

Tell us your e-mail address:

*First Name *Last Name
*CHOOSE AN OPTION

*All fields are required.

For US residents only.
All personal and/or medical information you have provided will be kept confidential and will not be used or distributed to anyone for any purpose other than what is explained in our privacy policy statement. We encourage you to read our privacy policy statement by clicking on this link: Review Shire privacy policy statement.

This consent will be in effect until such time as you opt out of the program.

NIICE Thanks for registering. We’re really looking forward to sending you updates.

Indication

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.

To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.

Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.

Safety and efficacy in pediatric patients below the age of 17 years have not been established.

Please click here for Full Prescribing Information.

Reference

  1. Xiidra [Prescribing Information]. Lexington, MA: Shire US.